Ignite Creation Date:
2024-05-06 @ 3:07 AM
Last Modification Date:
2024-10-26 @ 11:28 AM
Study NCT ID:
NCT02201420
Status:
COMPLETED
Last Update Posted:
2016-09-27
First Post:
2014-07-24
Brief Title:
Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposis Sarcoma and Lymphatic Drainage by SPECTCT
Sponsor:
Navidea Biopharmaceuticals
Organization:
Navidea Biopharmaceuticals
Study Overview
Official Title:
Evaluation of Technetium Tc 99m Tilmanocept Localization Retention and Distribution in Primary Cutaneous Kaposis Sarcoma KS and Lymphatic Drainage From KS Lesions by SPECTCT Imaging
Status:
COMPLETED
Status Verified Date:
2016-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study NAV3-12 is to determine the dissemination and localization of Tc 99m tilmanocept by SPECT and SPECTCT imaging in subjects with confirmed cutaneous KS This is a single center open-label within-subject study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None